Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1

Suneel D. Mundle, B. Yifwayimare Mativi, Jonathan D. Cartlidge, Bruce Dangerfield, La Tanya Broady-Robinson, Biaoru Li, Vilasini Shetty, Parameswaran Venugopal, Stephanie A. Gregory, Harvey D. Preisler, Azra Raza

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Myelodysplastic syndromes (MDS) have previously been reported to show competitively high rates of apoptosis and proliferation in the bone marrow (BM). Using a double-labelling technique in the present study, we demonstrated that a significantly high number of S-phase cells were simultaneously apoptotic (signal antonymy; SA) in MDS (mean ± s.e.m. 53.5 ± 6.7%, n = 24, P < 0.001). In contrast, SA was negligible in all other specimens studied, including normal control BM (n = 13) from non-Hodgkin's lymphoma (NHL) patients, BM from patients with de novo acute myelogenous leukaemia (1'AML; n = 5), or secondary AML that had transformed from MDS (2'AML; n = 10), or the solid tumours from patients with NHL (n = 9) or head and neck squamous cell carcinoma (HNSCC; n = 10). Subsequently, the expression of a transcription factor, E2F1, was studied in density-separated BM aspirate mononuclear cells from MDS patients (n = 9) and a normal control. Two separate sets of primers were used that recognized the regulatory retinoblastoma (Rb) protein-binding region and the functional DNA-binding region of E2F1. Interestingly, although the latter manifested the expected band (280 bp) in all samples, the Rb-specific primers showed the expected band (380 bp) in the normal and in 4/9 MDS specimens. Two other MDS specimens also showed a smaller band (~ 325 bp), whereas 3/9 MDS patients showed exclusively the smaller band. The levels of SA were significantly higher in those MDS cases that showed the smaller Rb-specific band either alone or in addition to the expected band (median 19.5%, n = 4, P = 0.037) than in those showing exclusively the expected band (median 0.4%, n = 3). Our present studies show SA as a characteristic feature of MDS and, importantly, demonstrate its link with an altered expression of E2F1 in some MDS patients.

Original languageEnglish (US)
Pages (from-to)376-381
Number of pages6
JournalBritish Journal of Haematology
Volume109
Issue number2
DOIs
StatePublished - Jun 24 2000
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Bone Marrow
Retinoblastoma
Non-Hodgkin's Lymphoma
Retinoblastoma Binding Proteins
E2F1 Transcription Factor
S Phase
Acute Myeloid Leukemia
Apoptosis
DNA

Keywords

  • Apoptosis
  • DNA synthesis
  • E2F1
  • Myelodysplastic syndromes
  • Signal antonymy

ASJC Scopus subject areas

  • Hematology

Cite this

Mundle, S. D., Mativi, B. Y., Cartlidge, J. D., Dangerfield, B., Broady-Robinson, L. T., Li, B., ... Raza, A. (2000). Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1. British Journal of Haematology, 109(2), 376-381. https://doi.org/10.1046/j.1365-2141.2000.01937.x

Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1. / Mundle, Suneel D.; Mativi, B. Yifwayimare; Cartlidge, Jonathan D.; Dangerfield, Bruce; Broady-Robinson, La Tanya; Li, Biaoru; Shetty, Vilasini; Venugopal, Parameswaran; Gregory, Stephanie A.; Preisler, Harvey D.; Raza, Azra.

In: British Journal of Haematology, Vol. 109, No. 2, 24.06.2000, p. 376-381.

Research output: Contribution to journalArticle

Mundle, SD, Mativi, BY, Cartlidge, JD, Dangerfield, B, Broady-Robinson, LT, Li, B, Shetty, V, Venugopal, P, Gregory, SA, Preisler, HD & Raza, A 2000, 'Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1', British Journal of Haematology, vol. 109, no. 2, pp. 376-381. https://doi.org/10.1046/j.1365-2141.2000.01937.x
Mundle, Suneel D. ; Mativi, B. Yifwayimare ; Cartlidge, Jonathan D. ; Dangerfield, Bruce ; Broady-Robinson, La Tanya ; Li, Biaoru ; Shetty, Vilasini ; Venugopal, Parameswaran ; Gregory, Stephanie A. ; Preisler, Harvey D. ; Raza, Azra. / Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1. In: British Journal of Haematology. 2000 ; Vol. 109, No. 2. pp. 376-381.
@article{247ba764c55c4348bbcd17a4feeb0550,
title = "Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1",
abstract = "Myelodysplastic syndromes (MDS) have previously been reported to show competitively high rates of apoptosis and proliferation in the bone marrow (BM). Using a double-labelling technique in the present study, we demonstrated that a significantly high number of S-phase cells were simultaneously apoptotic (signal antonymy; SA) in MDS (mean ± s.e.m. 53.5 ± 6.7{\%}, n = 24, P < 0.001). In contrast, SA was negligible in all other specimens studied, including normal control BM (n = 13) from non-Hodgkin's lymphoma (NHL) patients, BM from patients with de novo acute myelogenous leukaemia (1'AML; n = 5), or secondary AML that had transformed from MDS (2'AML; n = 10), or the solid tumours from patients with NHL (n = 9) or head and neck squamous cell carcinoma (HNSCC; n = 10). Subsequently, the expression of a transcription factor, E2F1, was studied in density-separated BM aspirate mononuclear cells from MDS patients (n = 9) and a normal control. Two separate sets of primers were used that recognized the regulatory retinoblastoma (Rb) protein-binding region and the functional DNA-binding region of E2F1. Interestingly, although the latter manifested the expected band (280 bp) in all samples, the Rb-specific primers showed the expected band (380 bp) in the normal and in 4/9 MDS specimens. Two other MDS specimens also showed a smaller band (~ 325 bp), whereas 3/9 MDS patients showed exclusively the smaller band. The levels of SA were significantly higher in those MDS cases that showed the smaller Rb-specific band either alone or in addition to the expected band (median 19.5{\%}, n = 4, P = 0.037) than in those showing exclusively the expected band (median 0.4{\%}, n = 3). Our present studies show SA as a characteristic feature of MDS and, importantly, demonstrate its link with an altered expression of E2F1 in some MDS patients.",
keywords = "Apoptosis, DNA synthesis, E2F1, Myelodysplastic syndromes, Signal antonymy",
author = "Mundle, {Suneel D.} and Mativi, {B. Yifwayimare} and Cartlidge, {Jonathan D.} and Bruce Dangerfield and Broady-Robinson, {La Tanya} and Biaoru Li and Vilasini Shetty and Parameswaran Venugopal and Gregory, {Stephanie A.} and Preisler, {Harvey D.} and Azra Raza",
year = "2000",
month = "6",
day = "24",
doi = "10.1046/j.1365-2141.2000.01937.x",
language = "English (US)",
volume = "109",
pages = "376--381",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1

AU - Mundle, Suneel D.

AU - Mativi, B. Yifwayimare

AU - Cartlidge, Jonathan D.

AU - Dangerfield, Bruce

AU - Broady-Robinson, La Tanya

AU - Li, Biaoru

AU - Shetty, Vilasini

AU - Venugopal, Parameswaran

AU - Gregory, Stephanie A.

AU - Preisler, Harvey D.

AU - Raza, Azra

PY - 2000/6/24

Y1 - 2000/6/24

N2 - Myelodysplastic syndromes (MDS) have previously been reported to show competitively high rates of apoptosis and proliferation in the bone marrow (BM). Using a double-labelling technique in the present study, we demonstrated that a significantly high number of S-phase cells were simultaneously apoptotic (signal antonymy; SA) in MDS (mean ± s.e.m. 53.5 ± 6.7%, n = 24, P < 0.001). In contrast, SA was negligible in all other specimens studied, including normal control BM (n = 13) from non-Hodgkin's lymphoma (NHL) patients, BM from patients with de novo acute myelogenous leukaemia (1'AML; n = 5), or secondary AML that had transformed from MDS (2'AML; n = 10), or the solid tumours from patients with NHL (n = 9) or head and neck squamous cell carcinoma (HNSCC; n = 10). Subsequently, the expression of a transcription factor, E2F1, was studied in density-separated BM aspirate mononuclear cells from MDS patients (n = 9) and a normal control. Two separate sets of primers were used that recognized the regulatory retinoblastoma (Rb) protein-binding region and the functional DNA-binding region of E2F1. Interestingly, although the latter manifested the expected band (280 bp) in all samples, the Rb-specific primers showed the expected band (380 bp) in the normal and in 4/9 MDS specimens. Two other MDS specimens also showed a smaller band (~ 325 bp), whereas 3/9 MDS patients showed exclusively the smaller band. The levels of SA were significantly higher in those MDS cases that showed the smaller Rb-specific band either alone or in addition to the expected band (median 19.5%, n = 4, P = 0.037) than in those showing exclusively the expected band (median 0.4%, n = 3). Our present studies show SA as a characteristic feature of MDS and, importantly, demonstrate its link with an altered expression of E2F1 in some MDS patients.

AB - Myelodysplastic syndromes (MDS) have previously been reported to show competitively high rates of apoptosis and proliferation in the bone marrow (BM). Using a double-labelling technique in the present study, we demonstrated that a significantly high number of S-phase cells were simultaneously apoptotic (signal antonymy; SA) in MDS (mean ± s.e.m. 53.5 ± 6.7%, n = 24, P < 0.001). In contrast, SA was negligible in all other specimens studied, including normal control BM (n = 13) from non-Hodgkin's lymphoma (NHL) patients, BM from patients with de novo acute myelogenous leukaemia (1'AML; n = 5), or secondary AML that had transformed from MDS (2'AML; n = 10), or the solid tumours from patients with NHL (n = 9) or head and neck squamous cell carcinoma (HNSCC; n = 10). Subsequently, the expression of a transcription factor, E2F1, was studied in density-separated BM aspirate mononuclear cells from MDS patients (n = 9) and a normal control. Two separate sets of primers were used that recognized the regulatory retinoblastoma (Rb) protein-binding region and the functional DNA-binding region of E2F1. Interestingly, although the latter manifested the expected band (280 bp) in all samples, the Rb-specific primers showed the expected band (380 bp) in the normal and in 4/9 MDS specimens. Two other MDS specimens also showed a smaller band (~ 325 bp), whereas 3/9 MDS patients showed exclusively the smaller band. The levels of SA were significantly higher in those MDS cases that showed the smaller Rb-specific band either alone or in addition to the expected band (median 19.5%, n = 4, P = 0.037) than in those showing exclusively the expected band (median 0.4%, n = 3). Our present studies show SA as a characteristic feature of MDS and, importantly, demonstrate its link with an altered expression of E2F1 in some MDS patients.

KW - Apoptosis

KW - DNA synthesis

KW - E2F1

KW - Myelodysplastic syndromes

KW - Signal antonymy

UR - http://www.scopus.com/inward/record.url?scp=0034038687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034038687&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2000.01937.x

DO - 10.1046/j.1365-2141.2000.01937.x

M3 - Article

VL - 109

SP - 376

EP - 381

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -